브리스톨-마이어스 스큅 (BMY) 주가 전망: 목표주가, 배당, 최신 뉴스

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.

Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM.

The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia.

In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer.

It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company는 전 세계에서 바이오제약 제품을 발굴·개발·라이선스·제조·마케팅·유통·판매하는 기업으로, 종양학, 혈액학, 면역학, 심혈관계 및 신경과학 적응증을 위한 치료제를 제공합니다.

주요 제품으로는 항암제 Opdivo(항암 적응증)와 피하 투여형 PD-1 억제제 Opdivo Qvantig(고형종양용), 류마티스 관절염·건선성 관절염 치료제 Orencia, 절제 불가능·전이성 흑색종 치료제 Yervoy 및 Opdualag, 빈혈치료제 Reblozyl, 재발·불응성 대형 B-세포 림프종 치료제 Breyanzi, 증상성 폐쇄성 비후성 심근병증 치료제 Camzyos 등을 보유하고 있습니다. 이 밖에 재발성 다발성 경화증 치료제 Zeposia, 재발·불응성 다발골수종 치료제 Abecma, 중등도-중증 판상 건선 치료제 Sotyktu, KRASG12C 변이 국소 진행성·전이성 비소세포폐암(NSCLC) 치료제 Krazati, 조현병치료제 Cobenfy, 뇌졸중/전신 색전증 위험 감소 및 DVT/PE 치료제 Eliquis, 다발골수종 구강면역조절제 Revlimid·Pomalyst/Imnovid, 필라델피아염색체 양성 만성 골수성 백혈병 치료제 Sprycel, 유방암 치료제 Abraxane, ROS1 양성 NSCLC(국소 진행성·전이성) 및 췌장암 치료제 Augtyro 등 광범위한 포트폴리오를 갖추고 있습니다.

제품은 도매상, 유통업체, 전문 약국, 소매점, 병원·클리닉 및 정부 기관 등에 공급되며, Arcus Biosciences, Inc.와는 신장암에서 종양 조절을 목표로 하는 치료요법 개발을 위한 전략적 협력을 진행 중입니다. 회사는 1887년에 설립되었고 본사는 Princeton, New Jersey에 있습니다(구명칭: Bristol-Myers Company).

• 주소: Route 206 & Province Line Road, Princeton, NJ 08543, United States

• 전화번호: 609 252 4621

• 웹사이트: https://www.bms.com

• 섹터: Healthcare

• 산업: Drug Manufacturers - General

• 직원 수: 32,500